1. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future

   • Linda M. de Vries
   • Pieter H. M. van Baal
   • Werner B. F. Brouwer

   Leading Article Open access 26 November 2018 Pages: 119 - 130

2. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

   • Ros Wade
   • Alessandro Grosso
   • Stephen Palmer

   Review Article 16 August 2018 Pages: 131 - 139

3. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Nasuh C. Büyükkaramikli
   • Saskia de Groot
   • Maiwenn J. Al

   Review Article Open access 08 September 2018 Pages: 141 - 153

   

4. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence

   • Richard Perry
   • George Braileanu
   • Paul Stevens

   Review Article Open access 13 October 2018 Pages: 155 - 167

   

5. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review

   • Edward T. Chiyaka
   • Van T. Nghiem
   • Phuc Le

   Systematic Review 27 October 2018 Pages: 169 - 200

   

6. Discrete Choice Experiments in Health Economics: Past, Present and Future

   • Vikas Soekhai
   • Esther W. de Bekker-Grob
   • Caroline M. Vass

   Systematic Review Open access 03 November 2018 Pages: 201 - 226

   

7. Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis

   • Tracey-Lea Laba
   • Helen K. Reddel
   • Stephen Jan

   Original Research Article 27 October 2018 Pages: 227 - 238

   

8. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

   • Eytan Stein
   • Jipan Xie
   • George Joseph

   Original Research Article 01 November 2018 Pages: 239 - 253

   

9. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

   • Andrea Marcellusi
   • Raffaella Viti
   • PITER Collaborating group available at www.progettopiter.it

   Original Research Article 30 October 2018 Pages: 255 - 266

   

10. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand

    • Bunchai Chongmelaxme
    • Pochamana Phisalprapa
    • Nathorn Chaiyakunapruk

    Original Research Article 15 November 2018 Pages: 267 - 278

    

11. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding

    • Thananan Rattanachotphanit
    • Chulaporn Limwattananon
    • Kittisak Sawanyawisuth

    Original Research Article 02 November 2018 Pages: 279 - 289

    

12. Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand

    • Bunchai Chongmelaxme
    • Pochamana Phisalprapa
    • Nathorn Chaiyakunapruk

    Correction 13 December 2018 Pages: 291 - 291